IRCT20200707048047N1 IRCT 2021-03-27 Islamic Azad University colchicine effect on persistent dyspnea in COVID19 Effects of colchicine on persistent dyspnea and pulmonary fibrosis of COVID-19 patients after hospital discharge 2020-07-22 anticipated 40 Complete https://irct.ir/trial/49766 interventional Randomization: Not randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Blinding description: in this study both control and treatment group receive supportive treatment. drug and placebo are packed in packages and are blindly distributed between patients.principle investigators and health care providers were blinded in this study. 2 COVID19. Intervention group: patients with history of Covid19 infection with persistent dyspnea and pulmonary fibrosis receive colchicine 0.5mg BID for 3 days and then 0.5 mg daily for 1 month. Undecided - It is not yet known if there will be a plan to make this available Justification or reason for indecision in sharing IPD is patients privacy